Trial Profile
Effects of Intensive Uric Acid Lowering Therapy With RDEA3170 (Verinurad) and Febuxostat in Patients With Albuminuria
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Febuxostat (Primary) ; Verinurad (Primary)
- Indications Hyperuricaemia; Proteinuria; Type 2 diabetes mellitus
- Focus Proof of concept; Therapeutic Use
- Acronyms CITRINE
- Sponsors AstraZeneca
- 01 Apr 2021 Primary endpoint (Urinary Albumin to Creatinine Ratio (UACR)) has been met.
- 01 Apr 2021 Primary endpoint (Urinary Albumin to Creatinine Ratio (UACR) Compared to Placebo) has been met.
- 01 Apr 2021 Results published in the American Journal of Kidney Diseases.